17 Dec 2025 Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers Investors | Therapeutics
08 Dec 2025 Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort Investors | Therapeutics
25 Oct 2025 Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets Investors | Therapeutics
21 Oct 2025 ESMO Phase 1a data for faridoxorubicin presented by Chris Coughlin and David Liebowitz Podcasts and Videos | Therapeutics
19 Oct 2025 Avacta Therapeutics presents compelling Phase 1a data for faridoxorubicin and the pre|CISION® platform at the European Society of Medical Oncology Annual Congress Therapeutics
13 Oct 2025 Research & Development Spotlight Series, Episode 12 Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
13 Oct 2025 Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium Therapeutics
09 Sep 2025 Avacta’s pre|CISION® Platform Shortlisted for the Technology of the Year Award at the AIM Awards Investors | Therapeutics